Teleflex has recalled a percutaneous thrombolytic device kit due to reports that a component could detach from the device and embolize. The Food and Drug Administration has classified this as a Class 1 recall, the most serious type, due to the potential for serious adverse health consequences or death. The company said it has received seven complaints about the issue, but no reports of long-term patient complications. It advises health care providers to immediately stop using and return all affected product, and identify all patients currently exposed to it. Providers also may report adverse reactions or quality problems using the product to the FDA's MedWatch program
 

Headline
The Federal Office of Rural Health Policy’s Rural Health Redesign Center will host a webinar on Sept. 24 at 2 p.m. ET, where hospital CEOs will discuss the…
Headline
Two individuals have died in Michigan in connection to the current multistate cyclosporiasis outbreak, the Michigan Department of Health and Human Services…
Headline
The AHA’s Living Learning Network, in partnership with the Centers for Disease Control and Prevention, July 22 released “Rural Sepsis Care in Action: Real-…
Headline
The Centers for Disease Control and Prevention July 14 released an advisory on the growing cyclosporiasis cases across the U.S. The advisory said that the…
Headline
The Centers for Disease Control and Prevention has reported 843 cases of cyclosporiasis across 31 states, with 86 people hospitalized. State health departments…
Headline
Angela Hewlett, M.D., professor of infectious diseases at the University of Nebraska Medical Center and medical director of the Nebraska Biocontainment Unit,…